Novartis is paying $125 million (€106 million) to acquire global rights to Sironax’s brain delivery platform, exercising an option it secured from the U.S.-Chinese biotech in July 2025. Sironax will retain rights to use the technology for selected assets.
Novo has entered a collaboration and licensing agreement with Danish biotech Orbis Medicines worth up to $1.4 billion (€1.2 billion) to discover oral macrocycle drugs for cardiometabolic diseases. Novo will also make an undisclosed strategic investment in Orbis.
Roche will pay Dualitas Therapeutics $36.5 million upfront in a research collaboration that could be worth up to $1 billion to discover bispecific antibodies for immune and inflammatory diseases.
As artificial intelligence reshapes life sciences research, two leading Elsevier Gold Open Access peer-reviewed journals, SLAS Discovery and SLAS Technology, invite contributions to Special Issues exploring how AI, automation and self-driving laboratories are transforming drug discovery. Submissions are accepted until 15 December 2026.
The French hearing-loss biotech has taken the first formal step toward a potential U.S. listing, as it advances its remaining gene therapy program into the clinic.
Thomas and Andreas Strüngmann have spent decades building pharmaceutical companies and backing biotech entrepreneurs, most famously BioNTech. Now, as a new generation takes a larger role in their family office, an award bearing their name is turning that investment philosophy into a search for Europe’s next biotech builders.
The appointment of Ponchi marking an important milestone in the company’s global commercial strategy and further strengthening its commercial leadership as the company continues to expand its presence in the global CDMO market.
Danish biotech ResoTher Pharma’s heart attack drug RTP-026 was well tolerated and showed early efficacy signals in a 66-patient Phase 2a trial, according to results announced Sept. 14 that clear a key condition for Swedish-listed Hunter Capital RTO 1’s planned reverse acquisition of the company.
GSK has agreed to acquire full global rights to a preclinical trispecific T-cell engager for multiple myeloma from China-based Chimagen Biosciences in a deal worth up to $750 million (€650 million), its second purchase from the company in under two years.
Agomab Therapeutics’ inhaled idiopathic pulmonary fibrosis (IPF) drug AGMB-447 showed lung-restricted exposure and inhibited its intended target in its first patient trial. The company plans to move the ALK5 inhibitor into phase 2 before the end of the year.
SLAS